Compare Charles River Laboratories Intl. Inc (CRL) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while abrdn Physical Palladium Shares ETF trades at $24.81. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| CRL | PALL | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $282.00 | $37.18 |
52-Week Low | $145.57 | $19.96 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
PALL trades at $24.85, down 1.04% over 24 hours. Technical indicators show a bullish trend with moving averages supporting a buy signal, though the RSI suggests potential overbought conditions. The stock underwent a 1:5 split effective May 18, 2026. Recent financial ratios are unavailable, limiting fundamental assessment. News sentiment highlights palladium's price weakness as a potential buying opportunity amid supply risks and industrial demand.
Outlook: PALL presents a speculative opportunity tied to palladium's recovery, with technical strength but limited fundamental data. Risks include commodity price volatility and macroeconomic factors. Investors should weigh the bullish technicals against the absence of current financial metrics and exposure to precious metal market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
